Exelixis Current Ratio 2006-2021 | EXEL

Current and historical current ratio for Exelixis (EXEL) from 2006 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Exelixis current ratio for the three months ending June 30, 2021 was 6.24.
Exelixis Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $1.59B $0.26B 6.24
2021-03-31 $1.43B $0.21B 6.72
2020-12-31 $1.45B $0.21B 7.06
2020-09-30 $1.41B $0.20B 6.99
2020-06-30 $1.40B $0.14B 9.78
2020-03-31 $1.14B $0.14B 8.09
2019-12-31 $1.01B $0.14B 7.08
2019-09-30 $0.97B $0.14B 6.89
2019-06-30 $0.96B $0.11B 8.64
2019-03-31 $0.95B $0.13B 7.56
2018-12-31 $0.90B $0.11B 8.51
2018-09-30 $0.79B $0.09B 8.66
2018-06-30 $0.69B $0.10B 6.87
2018-03-31 $0.57B $0.09B 6.67
2017-12-31 $0.49B $0.12B 4.21
2017-09-30 $0.47B $0.11B 4.32
2017-06-30 $0.40B $0.10B 4.12
2017-03-31 $0.47B $0.20B 2.31
2016-12-31 $0.47B $0.27B 1.75
2016-09-30 $0.42B $0.20B 2.09
2016-06-30 $0.35B $0.19B 1.83
2016-03-31 $0.34B $0.10B 3.36
2015-12-31 $0.18B $0.05B 3.42
2015-09-30 $0.21B $0.06B 3.71
2015-06-30 $0.09B $0.06B 1.52
2015-03-31 $0.13B $0.06B 2.13
2014-12-31 $0.17B $0.17B 0.98
2014-09-30 $0.22B $0.17B 1.27
2014-06-30 $0.26B $0.17B 1.51
2014-03-31 $0.30B $0.07B 4.20
2013-12-31 $0.27B $0.09B 3.04
2013-09-30 $0.31B $0.08B 3.93
2013-06-30 $0.38B $0.08B 5.03
2013-03-31 $0.38B $0.07B 5.66
2012-12-31 $0.43B $0.08B 5.29
2012-09-30 $0.49B $0.09B 5.78
2012-06-30 $0.21B $0.09B 2.37
2012-03-31 $0.25B $0.09B 2.86
2011-12-31 $0.23B $0.09B 2.48
2011-09-30 $0.25B $0.17B 1.47
2011-06-30 $0.28B $0.19B 1.47
2011-03-31 $0.32B $0.20B 1.64
2010-12-31 $0.18B $0.20B 0.92
2010-09-30 $0.19B $0.20B 0.94
2010-06-30 $0.24B $0.22B 1.06
2010-03-31 $0.18B $0.21B 0.84
2009-12-31 $0.23B $0.21B 1.11
2009-09-30 $0.31B $0.22B 1.43
2009-06-30 $0.21B $0.18B 1.16
2009-03-31 $0.23B $0.18B 1.31
2008-12-31 $0.27B $0.19B 1.43
2008-09-30 $0.12B $0.12B 0.99
2008-06-30 $0.17B $0.13B 1.30
2008-03-31 $0.25B $0.13B 1.85
2007-12-31 $0.28B $0.13B 2.14
2007-09-30 $0.29B $0.12B 2.44
2007-06-30 $0.24B $0.12B 2.08
2007-03-31 $0.29B $0.13B 2.30
2006-12-31 $0.26B $0.11B 2.35
2006-09-30 $0.14B $0.08B 1.73
2006-06-30 $0.19B $0.09B 2.18
2006-03-31 $0.22B $0.12B 1.76
2005-12-31 $0.20B $0.11B 1.80
2005-09-30 $0.21B $0.09B 2.42
2005-06-30 $0.20B $0.09B 2.15
2005-03-31 $0.14B $0.07B 2.09
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.824B $0.988B
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ? (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86